phosphoserine has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 2 studies
Phosphoserine: The phosphoric acid ester of serine.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, SY | 1 |
| Liu, YH | 1 |
| Chen, YJ | 1 |
| Yeh, YY | 1 |
| Huang, HM | 1 |
| Bernusso, VA | 1 |
| Machado-Neto, JA | 1 |
| Pericole, FV | 1 |
| Vieira, KP | 1 |
| Duarte, AS | 1 |
| Traina, F | 1 |
| Hansen, MD | 1 |
| Olalla Saad, ST | 1 |
| Barcellos, KS | 1 |
2 other studies available for phosphoserine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
CD69 partially inhibits apoptosis and erythroid differentiation via CD24, and their knockdown increase imatinib sensitivity in BCR-ABL-positive cells.
Topics: Antigens, CD; Antigens, CD34; Antigens, Differentiation, T-Lymphocyte; Apoptosis; CD24 Antigen; Cell | 2018 |
Imatinib restores VASP activity and its interaction with Zyxin in BCR-ABL leukemic cells.
Topics: Apoptosis; bcl-X Protein; Benzamides; Bone Marrow Cells; Cell Adhesion Molecules; Cell Proliferation | 2015 |